<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="72377">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02149342</url>
  </required_header>
  <id_info>
    <org_study_id>2013-001389-40</org_study_id>
    <nct_id>NCT02149342</nct_id>
  </id_info>
  <brief_title>Daylight-mediated Photodynamic Therapy of Actinic Keratoses:Comparing 2%HAL With 16%MAL</brief_title>
  <official_title>Daylight-mediated Photodynamic Therapy of Actinic Keratoses: a Randomized, Double-blinded Pilot Study Comparing Topical 2% Hexylaminolaevulinate With 16% Methylaminolaevulinate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Joint Authority for Päijät-Häme Social and Health Care</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Helsinki University Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Joint Authority for Päijät-Häme Social and Health Care</source>
  <oversight_info>
    <authority>Finland: Finnish Medicines Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot study compares two photosensitizers, hexylaminolaevulinate (HAL) and
      methylaminolaevulinate (MAL), in treatment of actinic keratoses. Study is conducted using
      randomized split-face design. Efficacy is assessed clinically, and histologically at 3 and
      12 months. Pain during and after treatments and adverse reactions at one week are recorded.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study recruites 16-20 voluuntering patients with symmetrical actinic damage on face or
      scalp. Treatment sites are randomized to receive either hexylaminolaevulinate (HAL) or
      methylaminolaevulinate (MAL) as photosenstizers (0.25mm-thick layer). Pre-treatment
      procedures include application of sunscreen for 15 minutes and curettage of the treatment
      area. Illumination is performed using 2 hours daylight-exposure. Efficacy is assessed
      clinically, and histologically at 3 and 12 months by blinded observers. Pain during and
      after treatments and adverse reactions at one week are recorded.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Histological lesion clearance</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Punch biopsies symmetrically on treatment fields prior to treatment and at 3 months, blinded observer (pathologist). HE- and p53-stainings.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical lesion clearance</measure>
    <time_frame>3 months and 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blinded observer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain assesment (visual analog scale)</measure>
    <time_frame>12 hours</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Pain is assessed in every 30 minutes during 2-hour sun-exposure and afterwards once in two hours until 9 p.m. (treatment day)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse reactions</measure>
    <time_frame>One week</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Blinded observer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clerance of field cancerization in hyperspectral images</measure>
    <time_frame>3 and 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Hyperspectral images prior to treatment and at 3 and 12 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Actinic Keratoses</condition>
  <arm_group>
    <arm_group_label>Hexylaminolaevulinate cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2% hexylaminolaevulinate (Hexvix, Photocure) mixed with Unguentum M (Allmiral)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Methylaminolaevulinate cream</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>16% methylaminolaevulinate (Metvix, Galderma)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hexylaminolaevulinate cream</intervention_name>
    <description>2% Hexylaminolaevulinate (Hexvix, Photocure) mixed with Unguentum M (Allmiral) cream</description>
    <arm_group_label>Hexylaminolaevulinate cream</arm_group_label>
    <other_name>HAL</other_name>
    <other_name>Hexvix, Photocure</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylaminolaevulinate cream</intervention_name>
    <description>MAL 16% is used as photosensitizer for daylight-PDT</description>
    <arm_group_label>Methylaminolaevulinate cream</arm_group_label>
    <other_name>16% Methylaminolaevulinate (Metvix, Galderma) cream</other_name>
    <other_name>MAL</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -Symmetrical actinic damage on face or scalp

        Exclusion Criteria:

          -  Pregnancy

          -  Lactation

          -  Allergy to photosensitizer

          -  Photodermatose
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Noora E Neittaanmäki-Perttu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Päijät-Häme Cnetral Hospital, Helsinki University Central Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mari Grönroos, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Päijät-Häme Central Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Noora E Neittaanmäki-Perttu, MD</last_name>
    <phone>+358407190362</phone>
    <email>noora.neittaanmaki@fimnet.fi</email>
  </overall_contact>
  <location>
    <facility>
      <name>Päijät-Häme Central Hospital</name>
      <address>
        <city>Lahti</city>
        <zip>15850</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Noora E Neittaanmäki-Perttu, MD</last_name>
      <phone>+358407190362</phone>
      <email>noora.neittaanmaki@fimnet.fi</email>
    </contact>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 25, 2014</lastchanged_date>
  <firstreceived_date>May 19, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Actinic keratoses</keyword>
  <keyword>Daylight-PDT</keyword>
  <keyword>Hexylaminolaevulinate</keyword>
  <keyword>HAL</keyword>
  <keyword>Methylaminolaevulinate</keyword>
  <keyword>MAL</keyword>
  <keyword>Hyperspectral imaging</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Keratosis</mesh_term>
    <mesh_term>Keratosis, Actinic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Methyl 5-aminolevulinate</mesh_term>
    <mesh_term>Aminolevulinic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
